Salirasib exerts its antitumour effects by interfering with the localisation of active Ras proteins to the plasma membrane, thereby attenuating downstream Ras signalling cascades, specifically the PI3K/Akt/mTOR pathways and Raf/MEK/ERK, essential for tumour cell proliferation and long‐term survival. Here, MTOR is linked to neoplasm.